New drug combo for advanced pancreatic cancer after first treatment
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a new drug combo (cadonilimab plus either S-1 or capecitabine) for people with advanced pancreatic cancer that has not spread to other organs and who have already tried one standard treatment. The goal is to see if this combination can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of pancreatic ductal adenocarcinoma (a common type of pancreatic cancer).
- Your cancer is locally advanced, meaning it has not spread to distant organs like the liver or lungs.
- You have already received standard first-line treatment for your cancer and it is no longer working.
- You are between 18 and 80 years old and your overall health is fair to good (able to do light daily activities).
- You do not have other active cancers or serious health problems like uncontrolled infections or autoimmune diseases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of three drugs—two pills and one infusion—for people with advanced pancreatic cancer who have already tried one or more treatments. It may help shrink tumors or slow the cancer's growth.
This trial tests a combination of three drugs (given through a vein and a pill) plus a chemotherapy infusion directly into your belly for stomach cancer that has spread to the lining of the abdomen. It specifically looks at a marker called Claudin 18.2 to see if this treatment works better for people with that marker.
This trial tests a combination of three drugs—anlotinib, benmelstobart, and chemotherapy—as a first treatment for pancreatic cancer that has spread. The goal is to see if this combo can shrink tumors or slow the cancer's growth better than current options.
This trial tests a new drug called IBI343 combined with standard chemotherapy for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a combination of chemotherapy (NALIRI-XELOX) plus a newer immunotherapy drug (AK104) as a first treatment for people with advanced pancreatic cancer that hasn't been treated yet. The goal is to see if this combination works better than standard treatments.
This trial tests a new drug (BMS-986340) plus standard chemo for people whose pancreatic cancer has spread or come back. The goal is to see if this combination works better.
Hear when a new Pancreatic Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.